SLC5A2 and heart failure: With their ability to improve symptoms and lower cardiovascular mortality, hospitalizations, and renal decline, SGLT2 inhibitors offer substantial clinical benefits for all three types of heart failure: HFrEF, HFmrEF, and HFpEF.